TABLE 2.
Patients' disease score at baseline and at week 12 and HiSCR achievement (group A: clindamycin 1% and group B: resorcinol 15%)
| Group A | Group B | |||
|---|---|---|---|---|
| Score | T0 n (%) | T12 n (%) | T0 n (%) | T12 n (%) |
| IHS4, mean ± SD | 3.7 ± 1.5 | 3.5 ± 1.1 | 3.9 ± 1.4 | 3.3 ± 2.8* |
| PAIN VAS, mean ± SD | 7.0 ± 1.9 | 5.1 ± 1.3* | 6.7 ± 1.8 | 0.4 ± 0.7*** |
| DLQI, mean ± SD | 17.2 ± 2.4 | 11.0 ± 2.9** | 16.8 ± 4.8 | 1.5 ± 2.1*** |
| Patients who achieved HiSCR | ||||
| Hurley stage I n (%) | 18 (52.9)** | 22 (84.6)*** | ||
| Hurley stage II n (%) | 20 (51.3)* | 30 (85.7)*** | ||
| Patients who achieved HiSCR | ||||
| IHS4 category mild n (%) | 22 (61.1)** | 24 (82.8)** | ||
| IHS4 category moderate n (%) | 16 (43.2)* | 25 (78.1)*** | ||
| Number of patients n (%) | 38 (52.0)* | 52 (85.3)*** | ||
| Average disease‐free survival, wk ± SD | 8.3 ± 3.2 | 12.5 ± 7.2 | ||
Abbreviations: DLQI, Dermatology Life Quality Index; HiSCR, Hidradenitis Suppurativa Clinical Response; IHS4, International Hidradenitis Suppurativa Severity Score System; SD, standard deviation; VAS, Visual Analogue Scale.
*
p < 0.05.
**
p < 0.01.
***
p < 0.001.